Testing
Lab tests and diagnostics for tracking healthspan: what to order, optimal ranges, and interpretation.
Biological risks of longevity interventions
Cancer risk, immune suppression, hormonal disruption, and other biological risks that longevity interventions can introduce.
The essential blood panel for tracking longevity
Which markers to test, optimal ranges vs normal ranges, how often to test, and what to do with the results.
Function-biomarker divergence: when the numbers and the body disagree
Why improving a biomarker does not always mean improving health, and how to detect when measurement and function diverge.
Intervention-specific risk patterns
Known and emerging risk patterns for specific longevity interventions including rapamycin, senolytics, NAD+ precursors, and hormones.
Measurement and interpretation failures in longevity science
How biomarker data gets misread, why surrogate endpoints mislead, and common interpretation errors in aging research.
Population mismatch: applying the wrong evidence to the wrong people
How age, sex, health status, and genetic background make population-level findings unreliable for individual decisions.
Protocol failure structures: systemic ways longevity protocols collapse
Structural failure patterns in longevity protocols including complexity overload, feedback loop blindness, and escalation traps.
Stop conditions and non-promotion rules
When to stop an intervention, what disqualifies a compound from promotion to regular use, and how to build in safety exits.
Translation failures: why animal results often do not replicate in humans
The structural reasons longevity interventions that work in mice frequently fail in human trials.